Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 13/20 | 0.52 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16845737 | 0.87 | IRAK4 (0.51) | MKNK1TRPA1IRAK4L3MBTL1 | |
| SCHEMBL18168040 | 0.84 | MKNK1 (0.57) | MKNK1TRPA1MKNK2IRAK4L3MBTL1 | |
| SCHEMBL16845644 | 0.84 | TRPA1 (0.44) | MKNK1TRPA1IRAK4L3MBTL1ROCK2 | |
| SCHEMBL16845708 | 0.83 | L3MBTL1 (0.57) | L3MBTL1ROCK2ROCK1 | |
| SCHEMBL16845739 | 0.82 | L3MBTL1 (0.43) | IRAK4L3MBTL1ROCK2ROCK1 | |
| SCHEMBL16845713 | 0.81 | AXL (0.43) | MKNK1IRAK4L3MBTL1ROCK2ROCK1 | |
| SCHEMBL16845710 | 0.81 | ROCK1 (0.47) | MKNK1TRPA1L3MBTL1ROCK2ROCK1 | |
| SCHEMBL22176838 | 0.80 | L3MBTL1 (0.41) | IRAK4L3MBTL1ROCK2ROCK1 | |
| SCHEMBL28087713 | 0.80 | L3MBTL1 (0.41) | IRAK4L3MBTL1ROCK2ROCK1 | |
| SCHEMBL27228043 | 0.79 | TRPA1 (0.41) | TRPA1IRAK4L3MBTL1ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951086-B2 | Indazolecarboxamides, processes for their preparation, pharmaceutical preparations comprising them and their use for producing medicaments | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-24 | — | — | US | disclosed |
| EP-3083586-B1 | NOVEL CARBOXAMIDES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS COMPRISING THEM, AND USE THEREOF FOR PRODUCING MEDICAMENTS | Bayer Pharma AG (DE) | 2018-04-18 | — | — | EP | disclosed |
| US-20160311833-A1 | NOVEL INDAZOLECARBOXAMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS COMPRISING THEM AND THEIR USE FOR PRODUCING MEDICAMENTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-27 | — | — | US | disclosed |
| WO-2015091426-A1 | NOVEL CARBOXAMIDES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS COMPRISING THEM, AND USE THEREOF FOR PRODUCING MEDICAMENTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311833-A1 | NOVEL INDAZOLECARBOXAMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS COMPRISING THEM AND THEIR USE FOR PRODUCING MEDICAMENTS | MALT1, APC, UACA | MKNK1 2625/4885TRPA1 2200/4885MKNK2 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.